Altesa raises $75M for oral respiratory med
Altesa BioSciences融资7500万美元用于口服呼吸系统药物

Altesa BioSciences has closed a $75 million Series B, enough to finance a Phase 2b study of its oral respiratory drug meant to prevent serious COPD exacerbations.
Altesa BioSciences完成了7500万美元的B轮融资，资金足以支持其用于预防严重COPD急性加重的口服呼吸系统药物开展2b期临床研究。